Epigenetic mechanisms of cancer progression and therapy resistance in estrogen-receptor (ER+) breast cancer
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024-05 · 1879 (3) · 189097
DOI: 10.1016/j.bbcan.2024.189097 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024-05. Verfasst von Eneda Toska. Beteiligte Einrichtung: Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University, Baltimore, MD, USA; Department of Biochemistry and Mo…. Hauptthemen laut MEDLINE: Breast Neoplasms, Epigenesis, Genetic, Drug Resistance, Neoplasm, Receptors, Estrogen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, AstraZeneca, Breast Cancer Alliance.
Abstract (Originalsprache)
Estrogen receptor-positive (ER+) breast cancer is the most frequent breast cancer subtype. Agents targeting the ER signaling pathway have been successful in reducing mortality from breast cancer for decades. However, mechanisms of resistance to these treatments arise, especially in the metastatic setting. Recently, it has been recognized that epigenetic dysregulation is a common feature that facilitates the acquisition of cancer hallmarks across cancer types, including ER+ breast cancer. Alterations in epigenetic regulators and transcription factors (TF) coupled with changes to the chromatin landscape have been found to orchestrate breast oncogenesis, metastasis, and the development of a resistant phenotype. Here, we review recent advances in our understanding of how the epigenome dictates breast cancer tumorigenesis and resistance to targeted therapies and discuss novel therapeutic interventions for overcoming resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University, Baltimore, MD, USA; Department of Biochemistry and Molecular Biology, Johns Hopkins School of Public Health, Baltimore, MD,…
Förderung
- NCI NIH HHS
- AstraZeneca
- Breast Cancer Alliance
- National Cancer Institute
Zitieren
APA
Toska, E. (2024). Epigenetic mechanisms of cancer progression and therapy resistance in estrogen-receptor (ER+) breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1879(3), 189097. https://doi.org/10.1016/j.bbcan.2024.189097
Vancouver
Toska E. Epigenetic mechanisms of cancer progression and therapy resistance in estrogen-receptor (ER+) breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(3):189097. doi:10.1016/j.bbcan.2024.189097
BibTeX
@article{Toska2024,
author = {Toska, Eneda},
title = {Epigenetic mechanisms of cancer progression and therapy resistance in estrogen-receptor (ER+) breast cancer},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2024},
volume = {1879},
number = {3},
pages = {189097},
doi = {10.1016/j.bbcan.2024.189097}
}
EUVIMED